Sign Out
Drug interaction studies have not been conducted in humans with Ustekinumab (Stelara) (see Pharmacology: Pharmacokinetics under Actions).
The effects of IL-12 or IL-23 on the regulation of CYP450 enzymes were evaluated in an in vitro study using human hepatocytes, which showed that IL-12 and/or IL-23 at levels of 10 ng/mL did not alter human CYP450 enzyme activities (CYP1A2, 2B6, 2C9, 2C19, 2D6, or 3A4). These results do not suggest the need for dose adjustments in patients who are receiving concomitant CYP450 substrates (see Pharmacology: Pharmacokinetics under Actions).
Live vaccines should not be given concurrently with Ustekinumab (Stelara) (see Precautions).
